The FDA has approved an extended-release tablet formulation of amantadine (Osmolex ER – Vertical/Osmotica) for once-daily treatment of Parkinson's disease (PD) and drug-induced extrapyramidal symptoms (EPS) in adults. An extended-release capsule formulation of amantadine (Gocovri) was approved in 2017 for treatment of levodopa-induced dyskinesia in patients with PD.1

STANDARD TREATMENT — Parkinson's Disease – The combination of levodopa and carbidopa is the most effective treatment for the motor symptoms of PD, but its long-term use leads to motor fluctuations and dyskinesia. Dopamine agonists such as pramipexole (Mirapex, and generics) and ropinirole (Requip, and generics) are less effective than levodopa; they can be used as monotherapy before the introduction of levodopa or as an adjunct to levodopa in patients with motor ... more      

Would you like to read the rest of this article?  Gain access below.